Company
CoreRx
Bend Bioscience is a top-tier US-based small-molecule pharmaceutical CDMO whose mission is to amplify the potential of medicines.
Also known as Bend Bioscience, CoreRx, Inc.
- Status
- Mergedas of 2026-09-20Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- United States
- Customers
- small and mid-sized pharmaceutical and biotech companies
- Legal name
- CoreRx, Inc.
- corerxpharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Record updated 28 September 2026
About
We offer bigger solutions and bolder science across the full range of small molecule capabilities and enabling technologies from pre-clinical to commercial scale with High Service and High Science for our clients, combining broad capabilities of a large CDMO with flexibility and speed of an expert partner. We design your optimal formulations with enabling technologies, desired release profiles and final dose forms, develop your molecules through the clinic, and scale up the manufacturing for the launch in our network of three specialized and newly expanded facilities in the USA.
Funding snapshot
- Total raised
- $15MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3M2019-03-14
Funding rounds
- Round, 2019
- $3M2019-03-14, SEC form D sold
- Round, 2017
- $5M2017-03-28, SEC form D sold, 3 investors
- Round, 2015
- $7M2015-03-19, SEC form D sold, 2 investors
About the company
- Status notes
- CoreRx, Societal CDMO, and Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO Offering